PatentJul 1, 2026, 07:02 AM
Seer's Key Patent Upheld by EPO; ITC Investigates Nanomics for Infringement
AI Summary
Seer, Inc. announced two significant developments bolstering its intellectual property. The European Patent Office upheld European Patent No. EP4056263, covering particle-based enrichment technology, following an opposition. Additionally, the U.S. International Trade Commission initiated an investigation into Nanomics Biotechnology Co., Ltd. for alleged infringement of five of Seer's U.S. patents, with Seer seeking to bar the importation and sale of Nanomics' infringing products. These actions, alongside a prior U.S. Patent Trial and Appeal Board decision upholding another patent, reinforce Seer's commitment to defending its proprietary technologies.
Key Highlights
- European Patent Office upheld European Patent No. EP4056263, covering particle-based enrichment technology.
- U.S. International Trade Commission instituted investigation into Nanomics Biotechnology Co., Ltd. for alleged infringement of 5 U.S. patents.
- Seer seeks a limited exclusion order to bar importation and sale of Nanomics' Proteonano kits and workstations.
- The Brigham and Women's Hospital joined the ITC action as a co-complainant.
- U.S. Patent Trial and Appeal Board upheld key claims of U.S. Patent No 11.435,360 on March 23, 2026.
- Seer holds over 250 patent applications and issued patents, including 84 issued worldwide.
Price Impact
More from SEER